Nektar And Collaborators Present Late-Breaking Results From Phase 2 Study Of NKTR-255 For The Treatment Of Radiation Induced Lymphopenia In Locally Advanced Non-Small Cell Lung Cancer Patients At SITC Annual Meeting; Demonstrated Statistically...
Nektar And Collaborators Present Late-Breaking Results From Phase 2 Study Of NKTR-255 For The Treatment Of Radiation Induced Lymphopenia In Locally Advanced Non-Small Cell Lung Cancer Patients At SITC Annual Meeting; Demonstrated Statistically...
Nektar And Collaborators Present Late-Breaking Results From Phase 2 Study Of NKTR-255 For The Treatment Of Radiation Induced Lymphopenia In Locally Advanced Non-Small Cell Lung Cancer Patients At SITC Annual Meeting; Demonstrated Statistically Significant Lymphocyte Recovery Compared To Historical Controls At Week 8
內克塔及合作伙伴在海豐國際年會上發佈了階段2研究NKTR-255治療局部晚期非小細胞肺癌患者放療引起的淋巴減少的最新結果；在第8周與歷史對照組相比，顯示出具有統計學意義的淋巴細胞恢復。
– NKTR-255 administered post completion of concurrent chemoradiation and in combination with durvalumab demonstrated statistically significant lymphocyte recovery compared to historical controls at week 8 –
- 在完成同時化療放療後給予NKTR-255，並與durvalumab聯合使用，在第8周顯示出與歷史對照組相比具有顯着統計學意義的淋巴細胞恢復。 -
– Pharmacodynamic data show NKTR-255 increased NK cell proliferation and markers of NK cell activation –
- 藥效動力學數據顯示NKTR-255增加了Nk細胞增殖和Nk細胞激活標誌物 -
SAN FRANCISCO, Nov. 7, 2024 /PRNewswire/ -- Nektar Therapeutics (NASDAQ:NKTR) and collaborators at The University of Texas MD Anderson Cancer Center today presented late-breaking results from a Phase 2 study evaluating NKTR-255 for the treatment of radiation induced lymphopenia after concurrent chemoradiation in locally advanced non-small cell lung cancer (NSCLC) patients at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting.
2024年11月7日，舊金山/美通社/ -- 內克塔治療（納斯達克股票代碼：NKTR）與德克薩斯大學MD安德森癌症中心的合作伙伴今日在海豐國際第39屆年會上發佈了一項階段2研究的最新結果，評估了NKTR-255用於治療局部晚期非小細胞肺癌患者在完成同時化療放療後放療引起的淋巴減少。
譯文內容由第三人軟體翻譯。
